It is true that the Supreme Court’s refusal to intervene leaves the federal appeals court’s rulings undisturbed, allowing the Medicare price-negotiation program to proceed as Congress drafted it. It is also true that, in the narrow sense in which appellate jurisprudence usually operates, the drug manufacturers’ constitutional challenge possessed a formal coherence that a court could, without prejudice, have entertained. The trouble — and here it is worth being precise about what “price negotiation” actually is, because the public discourse has the misleading habit of treating it as a direct subsidy transfer rather than a regulatory price ceiling — is that the program operates as a monopsony constraint on a pharmaceutical cartel that has treated Medicare as a captive market, requiring the government to write a check for whatever price it decrees. The industry’s legal assault on the Inflation Reduction Act was a desperate exercise in rent-extraction.

The pharmaceutical industry’s defense against that constraint rests on a single, repeated claim: that unregulated pricing is an economic necessity because research and development costs are astronomical. It is fair to say that R&D is capital-intensive, and it is equally fair to say that the accounting behind the industry’s cost tallies is deliberately, structurally opaque. “The few drugs that are truly innovative have usually been based on taxpayer-supported research done in nonprofit academic medical centers or at the National Institutes of Health,” Marcia Angell documented in her study of the sector; the private sector’s actual contribution is almost always limited to formulation tweaks, brand protection, and the maintenance of patent thickets that extend exclusivity long after the foundational work has entered the public domain. The engineering-substance discrimination here is simple: if the product is a novel mechanism of action discovered in a federal lab, the government’s role in negotiation is a return to the standard terms of that initial public investment.

The institutional substrate that has enabled this extraction is equally specific. The FDA’s prescription-user-fee structure — enacted in 1992 under the Prescription Drug User Fee Act, or PDUFA, which lets the companies whose drugs the agency reviews fund the reviewers’ salaries — has, by FY2025, shifted so that user fees supply 77% of the review program’s total costs. This budgetary dependency means the FDA’s regulatory timeline is directly financed by the monopoly rents the applicants collect once a drug hits the market. The result is a circular flow of capital: the public system pays companies to design products, pays them to apply for regulatory approval, and then allows them to price the approved products at whatever level the market will bear. Efficiency in this market is measured solely by the ability to keep prices pegged at the maximum an aging population can bear. Not a single Republican senator or representative voted for the Inflation Reduction Act, yet the industry’s political alliance could not secure judicial protection for its pricing floor.

The Court’s refusal to grant certiorari was predictable. The structural architecture of the price-negotiation program was designed to breach the insulation provided by regulatory capture. Twelve drugs sit on the initial negotiation list, with the first deals entering into effect in 2026. The legal ceiling that once insulated these firms has been set, and the exit of the judiciary shifts the battlefield from constitutional jurisprudence to the cold arithmetic of negotiation, forcing the industry to confront its monopoly-rent thesis head-on. The question is no longer whether the government can interfere, but how aggressively the federal monopsonist can extract those rents back before the firms find new avenues of extraction. The racket has lost its legal shield, but the racket itself remains. The records are open, the regulatory architecture is laid bare, and the margins remain high enough to absorb a bruising negotiation — though the labor required to defend those margins is already documented. The real work is building the structural leverage to ensure Medicare serves the elderly, not the pharmaceutical balance sheet.